Reactivation of a latent cytomegalovirus (CMV) infection is a significant cause of morbidity and mortality in hematopoietic stem cell transplant (HSCT) patients. Quantitative polymerase chain reaction (qPCR) assays and the CMV pp65 antigenemia test are used commonly to detect reactivation of CMV and guide pre-emptive therapy before disease onset. [1] [2] [3] Although qPCR assays are gaining popularity, guidelines for antiviral therapy based on these results are lacking. The CDC, Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation guidelines published in the year 2000, mention only non-quantitative PCR. 4 Different institutions have developed their own assays and local guidelines, and these vary depending on the specimen type (whole blood, plasma or a leukocyte preparation) and the design of the assay. Approaches have included treatment after one 5 or two positive PCR tests, 3 when the CMV viral load reaches a threshold value 6 , or a combination of these. 7 The recent publication by Verkruyse et al. 6 of their experience and recommendations at the Washington University School of Medicine, clearly different from that of the National Institutes of Health Clinical Research Center (NIH), prompted us to undertake the present study. At the Washington University School of Medicine, it has been recommended that for recipients of nonmyeloablative allogeneic stem cell transplants once daily ganciclovir should be initiated when a threshold CMV viral load reached 10 4 copies/ml of whole blood. 6 This recommendation was based in part on the observation that symptomatic disease did not occur at levels o10 4 copies/ml. 6 At the NIH viral loads 410 4 copies/ml are rarely observed in haematopoietic stem cell transplantation patients (unpublished data) and treatment is initiated at a viral load X10 3 copies/ml of whole blood. Guidelines for initiation of therapy at the NIH are, therefore, approximately one log different from those at the Washington University. At the NIH, in the absence of signs and symptoms of disease, treatment of patients with results between 250 and 1000 copies/ml is delayed until a result of X250 is confirmed on the next test. Treatment for patients with an initial result X10 3 copies/ml is initiated without delay. Using these guidelines, a 10% rate of CMV disease was observed at the NIH (unpublished data). This rate is similar to that observed in other studies 3, 5 and at the Washington University. 6 In addition to comparable rates of CMV reactivation and disease (albeit with management based on different thresholds of viremia), the patient populations at Washington University and the NIH seem to be similar. 6 Possible reasons for the quantitative difference between the Washington University and NIH PCR data were considered, and experiments were performed to determine them. Both laboratories perform the PCR test from whole blood collected in ethylenediamine tetraacetic acid tubes. In both centers, total nucleic acid was extracted using the MagNA Pure instrument (Roche, Indianapolis, IN, USA) and amplification was performed using real-time PCR technology. Genome equivalents per milliliter of whole blood were quantified from a standard curve. Differences between the assays were limited to the target gene used (polymerase vs glycoprotein B), the PCR instrument (Applied Biosystems Inc. 7500 vs the Roche LightCycler), the detection method (Taqman vs FRET hybridization probes) and the standards (reference standards from Advanced Biotechnologies Inc. (ABI, Columbia, MD, USA) with added human DNA (Promega, Madison, WI, USA) vs cloned target DNA). 8, 9 To determine if there was something inherent to each assay accounting for the differences in CMV data reported, 36 DNA extracts were exchanged between the two sites. When tested at Washington University, results were on average 0.60 log copies/ml higher than when tested at the NIH. For only one sample was the NIH result higher than the Washington University result. We suspected that this consistent difference resulted from the sources of quantification standards. To reproduce the Washington University standard curve at the NIH, ABI CMV DNA standards were purchased and human DNA was added according to the protocol provided by Washington University. When DNA extracts from 24 samples were repeated by qPCR at the NIH using both standard sets, results generated from the standard curve made according to the Washington University protocol were on average 0.76 log copies/ml higher than when using the NIH-protocol standard curve. As shown in Figure 1 , the quantification curve produced from the commercial source of CMV DNA was shifted compared to that generated from cloned plasmid standards. This would cause samples analyzed with the Washington University standards to be reported with higher copies/ml compared to those analyzed with the NIH standards, as shown in the figure with the hypothetical sample having a cycling threshold value of about 20. Fortunately, despite the differences in viral load calculated by the two assays, the slopes of the two curves are comparable. Thus, although numeric results are different, those differences will be fairly consistent over the range of reported results.
As few commercial qPCR assays are available and there is no agreement on which test method or specimen types have the best predictive values, systems developed in-house will likely continue to be commonly used in large transplantation centers. Clinicians must be aware that standardized materials for use in assays developed in-house are not available for many targets. Furthermore, the time and expense of validating a home-brew assay is significant and many laboratories would not choose to change their test method once therapeutic guidelines are established and housestaff are familiar with interpretation of test results. The guidelines set forth at the NIH and at Washington University appear to work well with the respective assays and patient populations. The results presented above underscore the need to evaluate qPCR assays within the patient population in which they are utilized and establish guidelines for therapy based upon clinical and laboratory data. Quantitative results between transplantation centers using different assays may not be directly comparable. Log CMV copies/ml PCR cycling threshold (Ct) Wash Univ stds (ABI with human DNA) NIH stds (plasmid clone without human DNA) 2.5 3.5 3 4 Figure 1 Comparison of standards used at Washington University and the NIH. Both sets of standards were analyzed simultaneously on the same LightCycler with the same PCR reagents at NIH. The dashed line shows that a higher number of copies/ml would be assigned to a hypothetical specimen with a cycling threshold value of 20 if the Washington University standards were used compared to the NIH standards.
